Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Monopar Therapeutics stock | $4.58

Learn how to easily invest in Monopar Therapeutics stock.

Monopar Therapeutics Inc is a biotechnology business based in the US. Monopar Therapeutics shares (MNPR) are listed on the NASDAQ and all prices are listed in US Dollars. Monopar Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Monopar Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MNPR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Monopar Therapeutics stock price (NASDAQ: MNPR)

Use our graph to track the performance of MNPR stocks over time.

Monopar Therapeutics shares at a glance

Information last updated 2021-10-24.
Latest market close$4.58
52-week range$4.28 - $10.55
50-day moving average $4.94
200-day moving average $5.35
Wall St. target price$40.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.65

Buy Monopar Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Monopar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Monopar Therapeutics price performance over time

Historical closes compared with the close of $4.58 from 2021-10-22

1 week (2021-10-15) -6.72%
1 month (2021-09-24) -10.55%
3 months (2021-07-23) -17.48%
6 months (2021-04-23) -21.84%
1 year (2020-10-23) -4.58%
2 years (2019-10-20) N/A
3 years (2018-10-20) N/A
5 years (2016-10-20) N/A

Monopar Therapeutics financials

Gross profit TTM $0
Return on assets TTM -26.49%
Return on equity TTM -43.55%
Profit margin 0%
Book value $1.86
Market capitalisation $57.6 million

TTM: trailing 12 months

Shorting Monopar Therapeutics shares

There are currently 80,464 Monopar Therapeutics shares held short by investors – that's known as Monopar Therapeutics's "short interest". This figure is 17.2% down from 97,168 last month.

There are a few different ways that this level of interest in shorting Monopar Therapeutics shares can be evaluated.

Monopar Therapeutics's "short interest ratio" (SIR)

Monopar Therapeutics's "short interest ratio" (SIR) is the quantity of Monopar Therapeutics shares currently shorted divided by the average quantity of Monopar Therapeutics shares traded daily (recently around 154738.46153846). Monopar Therapeutics's SIR currently stands at 0.52. In other words for every 100,000 Monopar Therapeutics shares traded daily on the market, roughly 520 shares are currently held short.

However Monopar Therapeutics's short interest can also be evaluated against the total number of Monopar Therapeutics shares, or, against the total number of tradable Monopar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Monopar Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Monopar Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0181% of the tradable shares (for every 100,000 tradable Monopar Therapeutics shares, roughly 18 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Monopar Therapeutics.

Find out more about how you can short Monopar Therapeutics stock.

Monopar Therapeutics share dividends

We're not expecting Monopar Therapeutics to pay a dividend over the next 12 months.

Monopar Therapeutics overview

Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. It also has a collaboration agreement with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in multiple types of cancer. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

Frequently asked questions

What percentage of Monopar Therapeutics is owned by insiders or institutions?
Currently 64.763% of Monopar Therapeutics shares are held by insiders and 1.484% by institutions.
How many people work for Monopar Therapeutics?
Latest data suggests 9 work at Monopar Therapeutics.
When does the fiscal year end for Monopar Therapeutics?
Monopar Therapeutics's fiscal year ends in December.
Where is Monopar Therapeutics based?
Monopar Therapeutics's address is: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091
What is Monopar Therapeutics's ISIN number?
Monopar Therapeutics's international securities identification number is: US61023L1089
What is Monopar Therapeutics's CUSIP number?
Monopar Therapeutics's Committee on Uniform Securities Identification Procedures number is: 61023L108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site